[1]峁 存,曾新春.急性心肌梗死经皮冠状动脉介入术治疗前后血清内皮细胞钙黏蛋白水平、血管生成素-2水平与预后相关性分析[J].陕西医学杂志,2022,51(10):1219-1222.[doi:DOI:10.3969/j.issn.1000-7377.2022.10.010]
　MAO Cun,ZENG Xinchun.Correlation between serum levels of VE-Cad,Ang-2 before and after PCI and prognosis of AMI patients[J].,2022,51(10):1219-1222.[doi:DOI:10.3969/j.issn.1000-7377.2022.10.010]
点击复制

急性心肌梗死经皮冠状动脉介入术治疗前后血清内皮细胞钙黏蛋白水平、血管生成素-2水平与预后相关性分析
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
51
期数:
2022年10期
页码:
1219-1222
栏目:
临床研究
出版日期:
2022-10-05

文章信息/Info

Title:
Correlation between serum levels of VE-Cad,Ang-2 before and after PCI and prognosis of AMI patients
作者:
峁 存1; 曾新春2
(1.延安市中医医院急诊科,陕西 延安 716000; 2.西安交通大学第一附属医院东院心血管内科,陕西 西安 710089)
Author(s):
MAO Cun; ZENG Xinchun
(Department of Emergency,Yan'an Hospital of Traditional Chinese Medicine,Yan'an 716000,China)
关键词:
急性心肌梗死;  经皮冠状动脉介入术;  主要不良心血管事件;  血管生成素-2;  内皮细胞钙黏蛋白;  相关性
Keywords:
Acute myocardial infarction;  Percutaneous coronary intervention;  Major adverse cardiovascular events;  Angiopoietin-2;  Endothelial cell cadherin;  Correlation
分类号:
R 542.2
DOI:
DOI:10.3969/j.issn.1000-7377.2022.10.010
文献标志码:
A
摘要:
目的:探析急性心肌梗死(AMI)经皮冠状动脉介入术(PCI)治疗前后血清内皮细胞钙黏蛋白(VE-Cad)水平、血管生成素-2(Ang-2)水平与预后的相关性。方法:选取急性心肌梗死患者64例作为研究对象,所有患者都给予PCI术治疗,在PCI治疗前与治疗后7 d检测患者的血清VE-Cad水平、Ang-2。随访调查患者的预后并进行相关性分析。结果:64例患者PCI治疗后7 d的血清VE-Cad含量高于PCI治疗前(P<0.05),血清Ang-2含量低于PCI治疗前(P<0.05)。64例患者随访到2022年2月1日,平均随访时间为(24.10±2.49)月,发生主要不良心血管事件(MACE)16例(MACE组),占比25.0%,其中心源性死亡2例、血管重建6例、非致死性心肌梗死5例、心力衰竭3例。Logistic回归模型分析显示血清VE-Cad、Ang-2水平为影响患者MACE预后的重要因素(均P<0.05)。受试者工作特征(ROC)曲线分析显示血清VE-Cad、Ang-2水平预测MACE预后的曲线下面积分别为0.797和0.789。结论:PCI治疗急性心肌梗死能促进血清VE-Cad含量升高与血清Ang-2含量降低,血清VE-Cad、Ang-2水平能有效预测急性心肌梗死患者的预后,也是影响患者的重要因素。
Abstract:
Objective:To investigate and analysis the correlation between serum levels of endothelial cadherin(VE-Cad),angiopoietin-2(Ang-2)before and after percutaneous coronary intervention(PCI)and prognosis of patients with acute myocardial infarction(AMI).Methods:A total of 64 cases of AMI patients were selected and treated with PCI.The serum VE-Cad,Ang-2 levels of the patients were detected before and 7 days after PCI treatment.The prognosis of the patients was followed up and the correlation analysis were carried out.Results:The serum VE-Cad content of 64 patients after PCI treatment were higher than that before PCI treatment(P<0.05),and the serum Ang-2 content of 64 patients were lower than that before PCI treatment(P<0.05).The 64 patients were followed up until 1 February 2022,with the average follow-up time of(24.10±2.49)years.The major adverse cardiovascular events(MACE)occurred in 16 patients(MACE group),accounted for 25.0%.There were 2 cases of cardiac death,6 cases of revascularization,5 cases of non-fatal myocardial infarction,and 3 cases of heart failure.Logistic regression model analysis showed that serum VE-Cad and Ang-2 levels were important factors affecting the prognosis of patients with MACE(all P<0.05).Receiver operating characteristic(ROC)curve analysis showed that the areas under the curve of serum VE-Cad and Ang-2 levels for predicting the prognosis of MACE were 0.797 and 0.789,respectively.Conclusion:PCI treatment of AMI can promote the increase of serum VE-Cad content and the decrease of serum Ang-2 content.Serum VE-Cad and Ang-2 levels can effectively predict the prognosis of AMI patients,and are also important factors affecting patients.

参考文献/References:

[1] 张 玲,郭利军.氢氯吡格雷与替格瑞洛在急性ST段抬高型心肌梗死合并2型糖尿病患者经皮冠状动脉介入治疗中的效果观察[J].陕西医学杂志,2020,49(10):1339-1342.
[2] 王业勤,刘桂清.急性心肌梗死冠脉造影血管开通后即刻与延迟放置支架对预后的影响[J].陕西医学杂志,2020,49(4):477-480.
[3] 王朝歆,李 岩,王 超,等.芎归六君子汤治疗急性心肌梗死疗效及对患者再灌注损伤后心功能、氧化应激水平的影响[J].陕西中医,2021,42(11):1549-1552.
[4] Cockburn J,Kemp T,Ludman P,et al.Percutaneous coronary intervention in octogenarians:A risk scoring system to predict 30-day outcomes in the elderly[J].Catheter Cardiovasc Interv,2021,98(7):1300-1307.
[5] Doll JA,Hira RS,Kearney KE,et al.Management of percutaneous coronary intervention complications:Algorithms from the 2018 and 2019 seattle percutaneous coronary intervention complications conference[J].Circ Cardiovasc Interv,2020,13(6):e008962.
[6] 宋金玉,杜 鑫,施继红,等.芪苈强心胶囊联合米力农对心肌梗死合并心力衰竭患者动脉血流和心功能的影响[J].陕西中医,2020,41(4):493-495.
[7] Gallo M,Blitzer D,Laforgia PL,et al.Percutaneous coronary intervention versus coronary artery bypass graft for left main coronary artery disease:A meta-analysis[J].J Thorac Cardiovasc Surg,2022,163(1):94-105.
[8] Guo L,Lv HC,Huang RC.Percutaneous coronary intervention in elderly patients with coronary chronic total occlusions:Current evidence and future perspectives[J].Clin Interv Aging,2020,15(9):771-781.
[9] Khan MR,Kayani WT,Pelton J,et al.Coronary artery bypass grafting versus percutaneous coronary intervention in patients with left ventricular systolic dysfunction[J].Cardiovasc Drugs Ther,2021,35(3):575-585.
[10] 郑 瑜,李树仁,刘 肖,等.比较STEMI患者PCI术后发生急性肾损伤不同评分的预测价值及远期预后[J].中国循证心血管医学杂志,2021,13(7):854-857.
[11] Mehran R,Vogel B,Levy P.Reducing the cost of managing patients with atrial fibrillation undergoing percutaneous coronary intervention with stenting[J].J Cardiol,2021,77(1):93-99.
[12] Nikolakopoulos I,Vemmou E,Karacsonyi J,et al.Latest developments in chronic total occlusion percutaneous coronary intervention[J].Expert Rev Cardiovasc Ther,2020,18(7):415-426.
[13] 崔路乾,董淑娟,李静超,等.预测ST段抬高型心肌梗死患者急诊经皮冠状动脉介入术后发生主要不良心血管事件风险的列线图模型构建[J].中华实用诊断与治疗杂志,2021,35(4):367-371.
[14] 宋 莉,徐大勇,周 鹏,等.STEMI患者服用替格瑞洛期间血清尿酸水平的变化及其对血小板反应性的影响初探[J].中华心血管病杂志,2021,49(2):170-175.
[14] Waliszewski M,Rosenberg M,Rittger H,et al.Endpoint selection for noninferiority percutaneous coronary intervention trials:A methodological description[J].Ther Adv Cardiovasc Dis,2020,14(9):17539-17544.
[15] Zuin M,Rigatelli G,Daggubati R.Cardiac intensive care management of high-risk percutaneous coronary intervention using the venoarterial ECMO support[J].Heart Fail Rev,2020,25(5):833-846.
[16] 孙号众,余晓凡,陈鸿武,等.一次和分次完全血运重建介入治疗对ST段抬高型急性心肌梗死合并多支血管病变患者临床预后的影响[J].中国介入心脏病学杂志,2021,29(11):607-611.
[17] 杨 洋,李 楠,赖红梅.急性前壁ST段抬高型心肌梗死患者介入治疗前血清血管内皮生长因子与左心室重构的关联性研究[J].中国心血管病研究,2021,19(9):818-823.
[18] Legnazzi M,Agnello F,Capodanno D.Prevention of contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention[J].Kardiol Pol,2020,78(10):967-973.
[19] 张飞飞,宋学莲,谢悦陶,等.直接经皮冠状动脉介入治疗应用血栓抽吸对STEMI患者心肌灌注及临床预后的影响[J].河北医科大学学报,2021,42(7):770-778.
[20] 田晋帆,杨雪瑶,左惠娟,等.成功经皮冠状动脉介入治疗对比药物治疗对不同左心室射血分数慢性完全性闭塞病变患者临床预后的影响[J].心肺血管病杂志,2021,40(9):890-895,901.

相似文献/References:

[1]雷晓敏,曹 蕊△.冠状动脉内注射硝普钠对行经皮冠状动脉介入术〖JZ〗急性心肌梗死患者心血管事件及左室功能的影响研究*[J].陕西医学杂志,2019,(10):1323.
[2]朱志坚,孙丽芳,陆志刚 .外周血中性粒细胞/淋巴细胞比值对急性心肌梗死患者预后的预测价值[J].陕西医学杂志,2019,(10):1326.
　ZHU Zhijian,SUN Lifang,LU Zhigang..Prognostic value of peripheral blood neutrophil/lymphocyte ratio for 〖JZ〗longterm prognosis in patients with acute myocardial infarction[J].,2019,(10):1326.
[3]王 颖,白 琳,张 洁,等.抑制炎性细胞因子与类风湿关节炎合并急性心肌梗死患者颈动脉斑块相关性研究*[J].陕西医学杂志,2019,(12):1679.
[4]贾凯侠,夏旭东△,田 心.体外反搏治疗急性心肌梗死临床疗效及对患者尿微量白蛋白影响研究*[J].陕西医学杂志,2020,49(1):90.
[5]赵 博,王银谦,王红燕.巨噬细胞移动抑制因子与冠心病关系Meta分析[J].陕西医学杂志,2020,49(1):125.
[6]王业勤,刘桂清△.急性心肌梗死冠脉造影血管开通后即刻与延迟放置支架对预后的影响[J].陕西医学杂志,2020,49(4):477.
　WANG Yeqin,LIU Guiqing..Effect of immediate stent and delayed stent on the prognosis of patients with acute myocardial infarction after coronary angiography opening[J].,2020,49(10):477.
[7]翟向伟,高宏勇△,王燕妮,等.冻干重组人脑利钠肽联合替罗非班对急性心肌梗死患者趋化素、半凝乳素-3水平的影响*[J].陕西医学杂志,2020,49(8):995.[doi:DOI:10.3969/j.issn.1000-7377.2020.08.021]
　ZHAI Xiangwei,GAO Hongyong,WANG Yanni,et al.Effect of lyophilized recombinant human brain natriuretic peptide combined with tirofiban on the levels of chemorin and Gal-3 in patients with acute myocardial infarction[J].,2020,49(10):995.[doi:DOI:10.3969/j.issn.1000-7377.2020.08.021]
[8]夏旭东,贾凯侠△.首次急性ST段抬高型心肌梗死行经皮冠状动脉介入术后心动过缓发生情况及危险因素分析[J].陕西医学杂志,2020,49(10):1303.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.027]
[9]张 玲,郭利军△.氢氯吡格雷与替格瑞洛在急性ST段抬高型心肌梗死合并2型糖尿病患者经皮冠状动脉介入治疗中的效果观察[J].陕西医学杂志,2020,49(10):1339.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.037]
　ZHANG Ling,GUO Lijun..Efficacy of hydroclopidogrel and ticagrelor in PCI in patients with acute ST-segment elevation myocardial infarction and type 2 diabetes mellitus[J].,2020,49(10):1339.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.037]
[10]渊 潭,李今朝.老年冠心病患者经皮冠状动脉介入术术后应用低剂量替格瑞洛的可行性及安全性研究[J].陕西医学杂志,2021,50(1):86.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.023]
　YUAN Tan,LI Jinzhao.Feasibility and safety of low dose ticagrelor after percutaneous coronary intervention in elderly patients with coronary heart disease[J].,2021,50(10):86.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.023]

备注/Memo

备注/Memo:
基金项目:陕西省重点研发计划项目(S2021-YF-YBSF-0623)
更新日期/Last Update: 2022-10-07